Analyst Reco. Cybin Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 02:55:37 2026-05-11 pm EDT			5-day change	1st Jan Change
5.085 ^USD	-4.24%		-3.40%	-37.53%

Apr. 30	Cybin Inc. will Change its Name to Helus Pharma	CI
Apr. 28	Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health	CI

Apr. 13	TD Cowen Initiates Coverage on Cybin With Buy Rating	MT
Feb. 02	Jefferies Initiates Coverage on Cybin With Buy Rating, CA$29.88 Price Target	MT
23-11-17	HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating	MT
23-08-15	Oppenheimer Adjusts Cybin Price Target to $4 From $4.50, Maintains Outperform Rating	MT
23-08-11	Canaccord Genuity Adjusts Price Target on Cybin to $5 From $6, Maintains Buy Rating	MT
23-07-03	Stifel Nicolaus Adjusts Cybin's Price Target to $1.13 From $1.10, Maintains Speculative Buy Rating	MT
23-07-03	Canaccord Genuity Trims Price Target on Cybin to $6 From $7, Maintains Buy Rating	MT
22-12-16	EF Hutton Initiates Cybin at Buy With $3 Price Target	MT
22-08-24	Stifel Nicolaus Adjusts Cybin Price Target to CA$3 From CA$8.25, Maintains Speculative Buy Rating	MT
21-11-23	Stifel Nicolaus Adjusts Cybin PT to CA$8.25 From CA$10, Maintains Speculative Buy Rating	MT
21-11-22	HC Wainwright Adjusts Cybin's Price Target to $10 From $8, Reiterates Buy Rating	MT
21-10-05	CYBIN : Oppenheimer Initiates Coverage on Cybin With Outperform Rating, $7 Price Target	MT
21-08-27	CYBIN : Canaccord Genuity Adjusts Cybin's Price Target to $7 From $6, Reiterates Buy Rating	MT
21-08-26	CYBIN : Cantor Fitzgerald Starts Cybin at Overweight with $9 Price Target	MT